None listed
Conditions
Interventions
None listed
Sponsors
Institute of Science Tokyo Hospital
Flatiron Health K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be included in this study: 1. Patients who visited the Institute of Science Tokyo Hospital between January 1, 2011 and June 30, 2029. 2. Diagnosed with one of the following types of cancer. - Breast cancer - Gastrointestinal cancers (esophageal cancer, gastroesophageal junction cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, gallbladder cancer, duodenal papillary carcinoma, intrahepatic bile duct cancer, gastrointestinal stromal cancer, small bowel cancer (including duodenal cancer), primary neuroendocrine tumor of the digestive tract, etc.) - Lung cancer (non-small cell lung cancer, small cell lung cancer, etc.) - Prostate cancer - Renal cancer - Urothelial carcinoma (bladder cancer, ureter cancer, and renal pelvis cancer, etc.) - Hematopoietic malignancies (leukemia, malignant lymphoma, multiple myeloma, myeloproliferative disorders, etc.) 3. Patients aged 18 and above 4. Patient(or a legal surrogate) has either confirmed willingness to participate in the study through one of the following methods, or has not expressed a decline to participate. - Written informed consent has been obtained using study-specific explanatory and consent documents. - For eligible patients who visited the institution on or after January 1, 2011, and are already deceased, no objection to participation has been received from the patient's legal surrogate after being provided with an opportunity to decline participation in this study,provided that this does not contradict the explicit wishes expressed by the patient during their lifetime. Surrogate: Spouse, parents, siblings, children/grandchildren, grandparents, relatives living together with the subject patient, or persons considered to be equivalent to such close relatives (excluding minors).
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Real-world overall survival, time-to-next-treatment, progression-free survival, time-to-treatment-discontinuation etc. | — |
Countries
Japan
Contacts
Public ContactAkiko Tobe
Institute of Science Tokyo Hospital Department of Precision Cancer Medicine
Outcome results
None listed